DPS has been designing Biopharmaceutical facilities from the first generation of recombinant proteins to monoclonal antibodies (mAbs) and modern-day advanced therapeutics. Our highly experienced teams design facilities for various platforms; mammalian cell culture (CHO cells), microbial (E.Coli, Pichia) and plant cell fermentation, and have developed expertise across a range of facilities from clinical to commercial manufacturing with large scale fixed stainless bioreactors, to smaller intensified processes in single-use bioreactors (SUBs)..
Our projects span a range of products including MAbs, interferons, fusion proteins, vaccines, antibody fragments, therapeutic enzymes, recombinant blood factors, and advanced cell and gene therapies (refer to our Novel Therapies page). Our Biopharmaceutical client base is extensive from emerging innovator clinical biopharma companies to large global biopharma companies and contract development manufacturing organizations (CDMOs).
At DPS, our teams are working on assignments embracing technology advances such as continuous manufacturing (perfusion and continuous downstream processing), advanced process analytical technology, improved single-use systems, modular, and podular designs. Our expertise spans drug substance, pegylation, formulation, and drug product facilities, including novel formulations (liposomes) and multi-format sterile fill and finish.
Engineering flexible facilities with an emphasis on your specific requirements and needs while focusing on innovative design and smart execution is our priority.
We welcome the opportunity for an introduction or to discuss any project, consulting, or staffing needs you may have.
Tell us about your project
and discover how DPS can help you today
